Follistatinsafety profile & UK regulatory status

This page summarises the published safety profile, contraindications, formulation interactions, and UK regulatory status for Follistatin as reported in the pre-clinical research literature. It is a research-orientation reference and not a clinical safety assessment. Follistatin is not licensed as a medicine in the United Kingdom and may not be supplied or administered to humans outside an authorised clinical-trial framework.

Safety profile

Follistatin safety data derive primarily from the ACE-083 clinical-development programme and pre-clinical work. The adverse-event profile at intramuscular local-delivery doses has been favourable: injection-site reactions predominate; occasional mild systemic effects (fatigue, headache). Clinical safety signals have generally been acceptable at doses tested, and the ACE-083 Phase II programmes in DMD and FSHD did not surface dose-limiting toxicity concerns even though efficacy endpoints were inconsistent. Theoretical safety concerns centre on the broader TGF-β family inhibition. TGF-β signalling is essential for tissue homeostasis in many contexts including immune regulation, tissue-repair fibrosis, and tumour suppression. Systemic follistatin exposure could theoretically produce inappropriate consequences in these systems including exaggerated wound-healing responses, immune-regulation shifts, and unpredictable interactions with concurrent fibrosis-modulating therapies. Local intramuscular delivery mitigates systemic exposure and consequent theoretical off-target concerns — this is a specific reason the ACE-083 development strategy prioritised local intramuscular administration over systemic delivery. Myostatin blockade specifically raises concerns about cardiac muscle effects — the cardiac muscle expresses myostatin and myostatin-receptor components, and inappropriate cardiac hypertrophy is a theoretical concern with systemic myostatin blockade. Bimagrumab's clinical-development history has surfaced some cardiac-imaging signals though not consistent decompensation-level adverse events. Pre-clinical and clinical data on follistatin have not consistently surfaced cardiac hypertrophy at pharmacological doses, but the theoretical concern is well-recognised and warrants echocardiographic monitoring in any chronic-dosing research protocol. Oncogenic concerns from TGF-β pathway modulation are established but complex — TGF-β signalling both promotes and suppresses tumour growth depending on context. Follistatin's implications for cancer risk are incompletely characterised. Activin blockade in ovarian and reproductive contexts requires specific consideration given the original follistatin discovery in ovarian follicular fluid — reproductive endocrinology effects of chronic follistatin dosing are plausible on mechanistic grounds. Contraindications on mechanistic grounds include: pregnancy and lactation (activin/TGF-β signalling in reproduction and development); known cardiac hypertrophy or cardiomyopathy; active malignancy where TGF-β modulation could be relevant; and concurrent anti-fibrotic pharmacology where mechanistic interactions are plausible. Grey-market use of follistatin for muscle-hypertrophy purposes has produced case reports of adverse events consistent with the theoretical concerns, though the reporting is limited. The absence of comprehensive clinical characterisation combined with the large-protein pharmacology (~35 kDa) makes grey-market administration particularly challenging to conduct with adequate safety-monitoring rigour.

UK regulatory status

Follistatin (recombinant human follistatin or follistatin-derived compounds like ACE-083) is not authorised as a medicinal product by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and holds no marketing authorisation in any jurisdiction. It is not a controlled substance under the Misuse of Drugs Act 1971. Follistatin is captured by the World Anti-Doping Agency (WADA) Prohibited List under category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) as a myostatin-pathway modulator. Athletes subject to anti-doping testing should treat follistatin and follistatin-derived compounds as prohibited both in-competition and out-of-competition. Research-grade material is available from research-chemical and biochemistry-reagent suppliers; possession for bona fide laboratory research is generally unrestricted in the UK. Supply for human use outside authorised clinical-trial frameworks engages the Human Medicines Regulations 2012 and is generally an offence. For animal research under ASPA, follistatin work in vertebrates requires standard project and personal licences.

What 'research-use-only' means in the UK

The UK regulatory position on research peptides sits across four distinct frameworks: MHRA medicines licensing, the Human Medicines Regulations 2012, the Misuse of Drugs Act 1971, and the WADA Prohibited List. Follistatin is not an MHRA-licensed medicine; possession for bona fide in-vitro or ex-vivo laboratory research is generally lawful, while supply or administration to humans engages the Human Medicines Regulations and is generally an offence. For animal-research use, additional permissions are required under the Animals (Scientific Procedures) Act 1986 (ASPA).

For the comprehensive UK regulatory reference covering all four frameworks, see the UK research peptide regulation 2026 reference.

Practical safety considerations for research

Sterility and endotoxin content of research-grade preparations remain the dominant practical safety variables for any injectable in-vivo work, regardless of the intrinsic safety profile of the active peptide. Batch-to-batch verification of HPLC purity and identity (by mass spectrometry where possible) and endotoxin testing by limulus amebocyte lysate (LAL) assay or recombinant Factor C (rFC) assay are standard due-diligence expectations. For research with vertebrate animals in the UK, ASPA project and personal licences are mandatory and the work must pass a local Animal Welfare and Ethical Review Body assessment.

For full Follistatin research context including mechanism, study citations, and references, see the main Follistatin research profile. For dosing and pharmacokinetic context, see the dosing reference and half-life reference pages.